Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$2.83 USD
-0.16 (-5.35%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.82 -0.01 (-0.35%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TSHA 2.83 -0.16(-5.35%)
Will TSHA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TSHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSHA
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
TSHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
Other News for TSHA
Fell Below 50 Day Moving Average appears for TSHA after 5.35% move
Is TSHA set to rally? Directional Movement Crossover Bullish shows up after rising 3.1%
What's Driving the Market Sentiment Around Taysha Gene Therapies?
TSHA forms 50 Day Moving Average Support on September 18
Is TSHA ready to move lower? 20 Day Moving Average Resistance shows up after tumbling 5.96%